Why Daiichi Sankyo’s Waiv collaboration matters for the next phase of ADC oncology trials
ADC trials need sharper patient selection. Daiichi Sankyo’s Waiv deal tests whether AI pathology can find response signals earlier.
Pharma & Biotech